Virtual Library
Start Your Search
David Palma
Author of
-
+
MS03 - New Frontiers in Oligometastases (ID 782)
- Event: WCLC 2018
- Type: Mini Symposium
- Track: Oligometastatic NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 10:30 - 12:00, Room 203 BD
-
+
MS03.01 - The Biology of Oligometastases: What Have We learned? (ID 11410)
10:30 - 10:45 | Presenting Author(s): David Palma
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
OA06 - Early Stage Lung Cancer: Outcomes and Interventions (ID 902)
- Event: WCLC 2018
- Type: Oral Abstract Session
- Track: Treatment of Early Stage/Localized Disease
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 13:30 - 15:00, Room 202 BD
-
+
OA06.06 - MISSILE-NSCLC: A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early-Stage Non-Small Cell Lung Cancer (ID 13028)
14:25 - 14:35 | Presenting Author(s): David Palma
- Abstract
- Presentation
Background
Stereotactic Ablative Radiotherapy (SABR) has emerged as a standard treatment option in patients with medically inoperable early-stage non-small cell lung cancer (NSCLC), yet the pathologic complete response (pCR) rate after SABR is unknown. Neoadjuvant SABR in operable patients has been proposed as a mechanism of improving local control and inducing anti-tumor immune activity.
a9ded1e5ce5d75814730bb4caaf49419 Method
This phase II study (NCT02136355) enrolled patients with biopsy-proven clinical T1-2N0M0 NSCLC who were candidates for surgical resection. Patients underwent neoadjuvant SABR using a risk-adapted fractionation of 54 Gy/3 fractions, 55 Gy/5 or 60 Gy/8. Surgical resection took place 10 weeks after SABR. Patients also underwent dynamic FDG-PET and dynamic contrast-enhanced CT prior to SABR and approximately 2 weeks prior to surgery. The primary endpoint was the pCR rate, and secondary endpoints included local, regional, and distant recurrence, quality of life using the FACT Trial Outcome Index (TOI), and toxicity.
4c3880bb027f159e801041b1021e88e8 Result
Accrual began in Sept 2014 and completed in August 2017 with 40 patients enrolled. Median age was 69 years (range 44–83 years), and 58% were female. Thirty-one patients (78%) had T1 tumors and 9 (23%) had T2 tumors; histology was adenocarcinoma (n=26; 65%), squamous cell (n=13; 33%) and NSCLC not otherwise specified (n=1; 3%). Baseline FEV1 was median 73% percent predicted (range 50%–117%). Nine patients (23%) received the 3-fraction regimen, 21 (53%) received 5 fractions and 10 (25%) received 8 fractions. Thirty-five patients underwent surgery and were evaluable for the primary endpoint. The pCR rate was 60% (95% CI 44%–76%). 30-day and 90-day post-surgical mortality rates were both 0%. Eighteen percent of patients had grade 3 or 4 toxicities, most commonly pulmonary in nature (Grade 4: atelectasis and respiratory failure [n=1]; Grade 3: pneumonia/pneumonitis [n=2]; bronchopleural fistula [n=1]). In the patients receiving surgery, 2-year outcomes were: overall survival 77%, local control 100%, regional control 53% and distant control 76%. There were no significant changes in FACT-TOI score within the first year of follow-up.
8eea62084ca7e541d918e823422bd82e Conclusion
The pCR rate after SABR for T1 and T2 NSCLC was 60%. Toxicity of the combined approach appears favorable, compared to historical series of surgery alone, and there was no perioperative mortality. Larger studies are needed to determine the clinical role of this combined treatment approach.
6f8b794f3246b0c1e1780bb4d4d5dc53Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
P2.12 - Small Cell Lung Cancer/NET (Not CME Accredited Session) (ID 961)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.12-13 - Effectiveness of Hypofractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Propensity Score Analysis (ID 13513)
16:45 - 18:00 | Author(s): David Palma
- Abstract
Background
Hypofractionated thoracic radiotherapy may be advantageous in limited-stage small-cell lung cancer (LS-SCLC) due to shorter overall treatment times, decreased resource utilization, and patient convenience. However, there are no randomized data comparing hypofractionated radiotherapy (HFRT; defined as 40-45 Gy in 15-20 fractions) and high dose conventionally-fractionated radiotherapy (CFRT; defined as >= 60 Gy in 2 Gy fractions) in LS-SCLC patients. The objective of this study was to compare the survival outcomes and toxicities of HFRT and CFRT using propensity score-matched retrospective data to simulate the setting of a clinical trial.
a9ded1e5ce5d75814730bb4caaf49419 Method
This retrospective study examined institutional records of patients diagnosed with LS-SCLC between January 2000 and December 2013 who were treated with HFRT or CFRT. Propensity scores were estimated by logistic regression using age, performance status, concurrent chemoradiation usage and prophylactic cranial irradiation (PCI) usage. Nearest neighbor-matching was performed on a 1:1 basis using a caliper distance of 0.1, without replacement. Overall survival (OS) and progression-free survival (PFS) endpoints were estimated by the Kaplan-Meier method and compared with log-rank tests. Cumulative incidences of normal tissue toxicity were compared with Fisher’s exact tests. A two-sided significance level of 0.05 was used.
4c3880bb027f159e801041b1021e88e8 Result
Among 398 LS-SCLC patients reviewed, 57 patients treated with HFRT and 61 patients treated with CFRT were included in the unmatched analysis. Five-year OS was 26% for the HFRT cohort and 24% for the CFRT cohort (p = 0.82). Five-year PFS was 22% for both cohorts (p = 0.79). Significant differences in age, performance status, concurrent chemoradiation usage and PCI usage were noted in the unmatched cohorts. After propensity score-matching, the balanced cohorts each contained 37 patients. Five-year OS was 25% and 27% (p = 0.72) and 5-year PFS was 25% and 24% (p = 0.63), respectively for the HFRT and CFRT cohorts. Incidence of any esophageal toxicity was not significantly different between the cohorts (92% HFRT vs. 84% CFRT, p = 0.60), though there was a trend towards a higher incidence of any pulmonary toxicity in the CFRT cohort (59% vs. 38%, p = 0.06). Skin toxicity was significantly higher for CFRT (39% vs. 14%, p = 0.01).
8eea62084ca7e541d918e823422bd82e Conclusion
OS and PFS were similar between HFRT and CFRT in balanced cohorts. HFRT was associated with a potentially reduced incidence of pulmonary and skin toxicity. As such, HFRT could result in an improved therapeutic ratio in patients with LS-SCLC. A randomized controlled trial would provide level 1 evidence in this comparison.
6f8b794f3246b0c1e1780bb4d4d5dc53
-
+
PL03 - Call to Action - Challenges Ahead (ID 851)
- Event: WCLC 2018
- Type: Plenary Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/26/2018, 08:15 - 09:45, Plenary Hall
-
+
PL03.03 - Beaming into the Future (ID 11651)
08:45 - 09:00 | Presenting Author(s): David Palma
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
